Home » Supplementary Announcement of Renfu Pharmaceutical Group Co., Ltd. on Renewing the Appointment of Accounting Firms

Supplementary Announcement of Renfu Pharmaceutical Group Co., Ltd. on Renewing the Appointment of Accounting Firms

by admin
Supplementary Announcement of Renfu Pharmaceutical Group Co., Ltd. on Renewing the Appointment of Accounting Firms


Stock code: 600079 Stock abbreviation: Renfu Pharmaceutical No.: Lin No. 2022-054

Special Note

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume individual and joint responsibility for the authenticity, accuracy and completeness of its content.

Renfu Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”) disclosed the “Announcement on Renewal of Accounting Firms” on April 28, 2022. The content of the announcement is now supplemented as follows:

Signature project partner: Zhang Wenjuan, partner of Daxin Certified Public Accountants, started practicing in Daxin Certified Public Accountants in 2005, obtained the qualification of certified public accountant in 2007 and engaged in auditing of listed companies, and began to provide audit services for the company in 2020. The audit reports of listed companies signed in the past three years include the annual audit reports of Huachangda Intelligent Equipment Group Co., Ltd., Tianfeng Securities Co., Ltd. and other companies.

Signing CPA: Liu Hongping, Chinese CPA, CTA, project manager of Daxin Certified Public Accountants, became a CPA in 2008, started practicing in Daxin CPA and engaged in auditing of listed companies in 2016, and began to provide company services in 2016 Audit service. In the past three years, he has mainly signed the audit report of listed companies for the company.

Project quality control reviewer: Xiao Xianmin, Chinese certified public accountant, review manager of the quality review department of Daxin Certified Public Accountants, became a certified public accountant in 2006, and has been engaged in audit-related work in Daxin Certified Public Accountants (special general partnership) since 2005, 2010 He has been engaged in audit quality review of listed companies and listed companies since 2003. The audit reports of listed companies reviewed in the past three years include Huachangda Intelligent Equipment Group Co., Ltd., Hubei Yihua Chemical Co., Ltd., Xinxiang Chemical Fiber Co., Ltd., Beijing Chengyitong Annual audit reports of companies such as Control Engineering Technology Co., Ltd.

See also  Energy costs: Private households are paying less again

Except for the above-mentioned supplements, other contents remain unchanged.

Special announcement.

Board of Directors of Renfu Pharmaceutical Group Co., Ltd.

April 29, 2022

Stock code: 600079 Stock abbreviation: Renfu Pharmaceutical No.: Lin No. 2022-055

Renfu Pharmaceutical Group Co., Ltd. on 2022

Supplementary Announcement of Expected Guarantee for Subsidiaries

Special Note

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume individual and joint responsibility for the authenticity, accuracy and completeness of its content.

Renfu Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Renfu Pharmaceutical” or the “Company”) held the 29th meeting of the 10th Board of Directors on April 26, 2022, reviewed and approved the “Regarding the Provision of Guarantees for Subsidiaries Expected in 2022” “Plan” and “Plan on Provision of Related Guarantees for Subsidiaries in 2022”, and on April 28, 2022, on the website of the Shanghai Stock Exchange (www.sse.com.cn) disclosed the “Renfu Pharma on 2022 Annual Announcement on Expecting to Provide Guarantees for Subsidiaries”, “Announcement of Renfu Medicine on Expecting to Provide Associated Guarantees for Subsidiaries in 2022”. In accordance with relevant regulatory requirements, the supplementary announcement on the above-mentioned annual guarantee forecast is as follows:

The company plans to list the estimated amount of guarantees provided to subsidiaries in 2022 according to whether the asset-liability ratio exceeds 70%, and submit it to the company’s 2021 annual general meeting for deliberation. The details of the relevant guarantee amount are as follows:

See also  Jufeng Investment Adviser: The new crown virus strain has not yet reached short-term A shares or still under pressure

(1) Guarantee quota for subsidiaries whose asset-liability ratio is less than 70%

(2) Guarantee quota for subsidiaries whose asset-liability ratio is higher than (or equal to) 70%

The company expects that the maximum amount of guarantee provided by the entities within the scope of the company’s consolidated statements in 2022 (including the company providing guarantees for subsidiaries and subsidiaries providing guarantees for their subsidiaries) will not exceed RMB 8,958.3 million, of which the asset-liability ratio is less than 70% of the guarantors are expected to provide a guarantee amount of no more than RMB 7,583,300,000, and those with an asset-liability ratio higher than (or equal to) 70% are expected to provide a guarantee amount of no more than RMB 1,375,000,000. The company proposes to the general meeting of shareholders to authorize the board of directors to review and approve the guarantee amount applied by each subsidiary that meets the above conditions within the scope of the above-mentioned items. The company’s operating conditions can be adjusted and used internally, but the guarantee amount of the guarantee object whose asset-liability ratio is lower than 70% shall not be adjusted and used for the guarantee object whose asset-liability ratio is higher than (or equal to) 70%.

Except for the above supplementary contents, other contents of the company’s 2022 annual guarantee forecast remain unchanged, and relevant matters still need to be submitted to the company’s general meeting of shareholders for deliberation.

Special announcement.

Board of Directors of Renfu Pharmaceutical Group Co., Ltd.

April 29, 2022

See also  Nubia Z50 image performance flagship officially released, price starts at 2999 yuan- DoNews
  声明:新浪网独家稿件,未经授权禁止转载。
-->

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy